Week of November 26, 2012: Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of November 26, 2012: Takeda Forms New Global Medical Affairs Department; UCB, NewBridge Pharmaceuticals Partner for Middle East and African Markets; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Takeda Pharmaceutical has established a new organization (Global Medical Affairs Japan Department) in Takeda Development Center Japan, Pharmaceutical Development Division, with appointment of its senior leadership, effective Dec. 1, 2012. Along with this, the company’s Strategic Medical Research Planning Division, currently under Takeda Development Center Japan, will be positioned under Global Medical Affairs Japan Department. Koki Nakamura has been named general manager of the new department. Read More

The biopharmaceutical company UCB has announced that Exemed Pharmaceuticals, a manufacturer of APIs, will acquire UCB’s production facility in Vapi, India. The deal includes a multiyear supply agreement between UCB and Exemed as well as the transfer of UCB Vapi’s staff of approximately 80 members to Exemed. Read More

In a separate deal, UCB and NewBridge Pharmaceuticals, a specialty therapeutics company have agreed to make UCB’s core products Cimzia (PEGylated anti-tumor necrosis factor), Vimpat (lacosamide), and Neupro (rotigotine), available in several Middle East and African countries. Under the agreement, NewBridge acquires the rights to Cimzia, Vimpat, and Neupro from the RX Group, UCB’s previous partner in the region. UCB will operate with its new partner for the region and will supply NewBridge with the three products on an exclusive basis. NewBridge will also be responsible for managing the local regulatory approval process, future commercialization, and pharmacovigilance in each of the relevant countries. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here